To develop potential new Tc radiopharmaceuticals, a novel compound [99mTc(CO)2(NO)(EHIDA)]0 (EHIDA: 2,6-diethylphenylcarbamoylmethyliminodiacetic acid) has been prepared by reacting [99mTc(CO)3)(EHIDA)]− with NOBF4 both in water and acetonitrile. The conversion of [99mTc(CO)3)(EHIDA)]− to [99mTc(CO)2(NO)(EHIDA)]0 was supported by TLC, HPLC and eletrophoresis. The radiochemical purity (more than 99%) was proved by TLC and HPLC. The biodistribution in mice demonstrated that [Tc(CO)2(NO)(EHIDA)]0 showed higher uptake in blood, kidney and lung (15 min, blood: 19.24±2.95; kidney: 13.61±3.49; lung: 10.81±1.09.) but a lower uptake in liver (15 min, 5.73±0.74). The slower clearances (120 min, blood: 12.75±1.34; kidney: 13.61±3.49) from blood and kidney were also found. This research describes two methods for the conversion of [99mTc(CO)3]+ into [99mTc(CO)2)(NO)]2+ by using NOBF4 as the source of NO+ both in organic solvent and water. The latter method offers the possibility to introduce the NO-group in high yield in water.